Cardinal Health’s Cordis Business Will Distribute Medinol’s Coronary Stent Portfolio in the United States


October 18, 2017—Cardinal Health recently advised that it has entered into a long-term, exclusive distribution agreement with Medinol that enables Cordis, Cardinal Health’s interventional vascular business, to sell Medinol’s coronary stent portfolio in the United States.

Cordis will transition to being the sole distributor of Medinol’s NIRxcell bare metal stent in the coming weeks and will be the sole distributor of Medinol’s EluNIR drug-eluting stent upon regulatory approval in the United States. EluNIR, which is coated with ridaforolimus, is an investigational device and is not approved for commercial use in the United States, advised the company.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.